Posted inBriefs

Compounding pharmacies can resume making tirzepatide as F.D.A. reconsiders shortage

“The Food and Drug Administration said in a court filing late Friday that it would allow pharmacists to continue making compounded versions of tirzepatide — the active ingredient in Eli Lilly’s diabetes and weight loss drugs Mounjaro and Zepbound — while it reconsiders its decision to remove the drug from its nationwide shortage list,” Berkeley Lovelace Jr. […]

Gift this article

Clicky